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.2012.11.Abstract Background: Studies revealed that insulin resistance is associated with ﬁbrosis progres-
sion and has negative impact on sustained virological response after standard antiviral therapy in
patients with chronic hepatitis C (CHC).
Aim: To assess the role of IR on progression of liver ﬁbrosis and early virological response
(EVR) rates in patients with chronic hepatitis C infection.
Patients and methods: The study population comprised 79 subjects who underwent combination
therapy for CHC. Laboratory investigations in the form of glucose, insulin, bilirubin, alanine ami-
notransferase (ALT), cholesterol and triglycerides and liver biopsy were done for all patients. Insu-
lin resistance was calculated using the homeostasis model of IR (HOMA-IR).
Results: IR was increased (>2 IU) in 31 (40.7%) of patients. Early virological response was
achieved among 37 patients (48.7%). No difference in EVR, viral load or grade of liver ﬁbrosis
between patients with and without IR. A signiﬁcant positive correlation was found between IR
and liver steatosis.
Conclusion: Insulin resistance is a common ﬁnding in CHC, it is associated with increase liver
steatosis. However it has no impact on EVR to combined interferon ribavirin therapy, viral load
or necroinﬂammation.
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0011. Introduction
Insulin resistance (IR) is a condition in which higher than nor-
mal insulin concentrations are needed to achieve normal met-
abolic responses, or in which normal insulin concentrations
fail to elicit a normal metabolic response [1].tion and hosting by Elsevier B.V. All rights reserved.
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of metabolic syndrome, and the main pathogenetic factor for
non alcoholic fatty liver disease (NAFLD), the hepatic mani-
festation of the metabolic syndrome [2].
Recently, several studies are focused on the relationship of
insulin resistance and chronic hepatitis C (CHC). Different
lines of evidence have found that IR is a common feature in
patients with CHC especially with genotypes 1 and 4 [3,4].
Studies in animal models using genotype 1 constructs revealed
that the development of IR occurred early and in the absence
of liver injury or body weight gain, providing support for a di-
rect link between CHC infection and IR [5]. The clinical rele-
vance of IR in HCV arises from its ability to promote
hepatic inﬂammation and ﬁbrosis and to impair response to
antiviral therapy [4,6].
However, Contrasting data exist on the role of IR as a pre-
dictor of sustained virological response (SVR) in the setting of
both HCV mono-infected and HIV/HCV coinfected subjects
[7–9].
The reference method for assessment of IR is the glucose
clamp technique; however this method is expensive and labori-
ous. The homeostasis model assessment (HOMA) of insulin
sensitivity was proposed as a simple and inexpensive alterna-
tive and is a good reﬂection of that assessed by the glucose
clamp technique [10].
EVR (Early Virological Response): EVR means that hepa-
titis C viral load has dropped by 99% (2logs), or is undetect-
able after 12 weeks of HCV treatment. An EVR is a good
predictor of the ultimate response to HCV treatment. If a per-
son does not have an EVR, their chance of SVR is very low (1–
4%). Usually, HCV treatment is discontinued in people who
do not have an EVR [11].
The aim of the study was to assess the effect of insulin resis-
tance, measured by HOMA test for insulin sensitivity, on the
early virological response to hepatitis C virus therapy in
HCV infected patients.Table 1 Demographic and laboratory characteristics of the
patients.
Mean ± SD Range
Age, years 47 ± 12 18–70
BMI, kg/m2 25.6 ± 1.5 22.5–29.7
Waist,cm 84.6 ± 6.3 68–94
ALT, IU/dl 55.8 ± 48.9 10–250
Triglycerides, mg/dl 196.2 ± 121.6 135–123
Cholesterol, mg/dl 213.8 ± 24.4 159–373
FBG, mmol/L 4.9 ± 0.6 3.8–6.7
HOMA-IR 2.6 ± 5 0.2–12.8
BMI, body mass index; ALT, alanine aminotransferase; FBG,
fating blood glucose; HOMA-IR, homeostasis model assessment;
IR, insulin resistance.2. Patients and methods
2.1. Patients
We prospectively evaluated 76 patients with chronic HCV
infection recruited from National Liver and Tropical Disease
Institute. Patients were subjected to detailed history and
clinical examination. Liver biopsy and laboratory investiga-
tions were done for all patients before starting therapy.
All patients were enrolled in the study after signing the
informed consent and approval of ethical committee in na-
tional research center.
Patients were initiated on treatment with subcutaneous
pegylated interferon alfa-2a (180 lg/week) plus oral ribavirin
(1000 or 1200 mg/day).
Exclusion criteria were: patients with hepatitis B infection
or human immunodeﬁciency virus infection, autoimmune or
metabolic liver diseases, diabetes mellitus, patients with body
mass index (BMI) P30 kg/m2, patients not eligible for inter-
feron therapy. Also we excluded patients who were previously
treated by any drug that may affect the results.
The end point was to assess early virological response and
its relation to IR. Early virological response (EVR) was de-
ﬁned as HCV RNA undetectable at week 12.2.2. Laboratory assessment
Blood samples were collected after a 12-h overnight fast and
deposited in dry tubes with EDTA. The plasma was separated
immediately using refrigerated centrifugation at 2500–
3000 rpm for a period of 10 min. The samples were processed
after conservation at 20 C. Blood was collected for the
determination of the serum levels of plasma glucose, insulin
and alanine aminotransferase (ALT), cholesterol, triglycerides
were measured after precipitation with polyanions Plasma glu-
cose was measured immediately on fresh samples collected in
oxalate tubes. Serum insulin was determined by a radioimmu-
noassay (Phasdaseph Insulin RIA; Pharmacia and Upjohn
Diagnostics AB, Uppsala, Sweden) [12].
Insulin resistance (IR) was calculated using the homeostasis
model of IR (HOMA-IR).
HOMA-IR = fasting glucose (mmol/L) · fasting insulin
(lU/ml)/22.5 [12,13]. Patients with HOMA IR >2 were con-
sidered to have IR [14].
Hepatitis CV RNA was assessed before and 12 weeks after
therapy. Viral load less than 106 copies/ml was considered mild
viremia, between 106 and 108 copies/ml moderate viremia,
more than 108 copies/ml severe viremia.
2.3. Histopathological examination
An ultrasound guided percutaneous liver biopsy was per-
formed for all subjects. The degree of necroinﬂammatory
activity and of ﬁbrosis was scored by an expert hepatopathol-
ogist based on the Ishak score [15] (F0, no ﬁbrosis; F1, portal
ﬁbrosis without septa; F2, portal ﬁbrosis with rare septa; F3,
numerous septa without cirrhosis; F4, cirrhosis). Necroinﬂam-
mation scored from 6 to 14. Hepatic steatosis was scored as the
percentage of hepatocytes containing macrovesicular fat drop-
lets. The grading was conducted as follows: grade 0, no steato-
sis; grade 1, <33% of hepatocytes affected; grade 2, 33–66%
of hepatocytes affected; grade 3, >66% of hepatocytes af-
fected [16].
2.4. Statistical analysis
Data were presented as mean and standard deviation (SD) and
percentage. The data were analyzed by SPSS version 14 (SPSS
Inc., Chicago, IL, USA). The following tests of signiﬁcance
were used: t-test between means to analyze differences between
Table 3 Correlation between Insulin resistance and other
parameters.
Insulin resistance
r p
Age 0.311 0.006
Weight 0.120 0.440
Height 0.048 0.881
BMI 0.097 0.242
Waist 0.127 0.244
ALT 0.007 0.890
Triglycerides 0.056 0.285
Cholesterol 0.061 0.463
FBG 0.016 0.642
Necroinﬂammation score 0.083 0.677
Steatosis 0.255 0.03*
BMI, body mass index; ALT, alanine aminotransferase; FBG,
fating blood glucose.
* p Value is signiﬁcant.
Table 2 Difference between patients with and without insulin resistance.
Variables Patients with IR 6 2
n= 45
Patients with IR > 2
n= 31
p Value
Age, years, mean ± SD 43.3 ± 13.1 52.6 ± 8.1 <0.001*
Sex n (%)
Males (n= 51) 27(60) 24(77.4) 0.961
Females (n= 25) 18(40) 7(22.6)
BMI, kg/m2, mean ± SD 25.5 ± 1.6 25.7 ± 1.1 0.6
Waist, cm, mean ± SD 83.2 ± 6.8 86.6 ± 5.1 0.02*
ALT, IU/dl, mean ± SD 53.1 ± 52.9 56.5 ± 44.1 0.8
Triglycerides, mg/dl, mean ± SD 206.6 ± 159.0 180.1 ± 12.8 0.4
Cholesterol, mg/dl mean ± SD 216.3 ± 29.5 211.1 ± 14.6 0.4
FBG, mmol/dl, mean ± SD 4.9 ± 0.6 4.9 ± 0.7 0.8
Fasting insulin IU/dl, mean ± SD 4.6 ± 2.9 24.2 ± 13.8 <0.001
Viral load n (%)
 Mild viremia 17 (37.8%) 17 (54.8%)
0.2
 Moderate viremia 18 (40%) 6 (19.4.0%)
 Marked viremia 10 (22.2%) 8 (25.8%)
Necroinﬂammation mean ± SD 10.8 ± 2.1 10.9 ± 1.8 0.6
Steatosis n (%)
633% 9 (20%) 3 (9.7%) 0.2
>33% 36 (80%) 28 (90.3%)
Fibrosis, n (%)
 Grades 1–2 14 (31.1%) 8 (26.7%)
0.7 Grades 3–4 31 (68.9%) 23 (73.3%)
EVR, n (%)
 Responders 21 (43.3%) 16 (51.6%)
0.5 Non responders 24 (56.7%) 15 (48.4%)
BMI, body mass index; ALT, alanine aminotransferase; EVR, early virological response.
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by v2 tests. Two-tailed p-value <0.05 was considered statisti-
cally signiﬁcant.
3. Results
3.1. Patients characteristics
The current study comprised 76 patients with chronic HCV
infection; they were 51 men and 25 women. Demographicand laboratory characteristics of the patients are presented in
Table 1.
Before starting treatment viral load was mild (<106 copies/
ml) in 34 patients (44.7%), moderate (106–108 copies/ml) in 24
patients (31.6%) and severe (>108 copies/ml) in 18 patients
(23.7%).
Insulin resistance assessed by HOMA test ranged from 0.2
to 12.8 with mean of 2.6. Thirty one (40.7%) patients had insu-
lin resistance >2.
Histopathological evaluation of liver biopsies showed that
the score of necroinﬂammation ranged from 6 to 14 with mean
value of 10.7 ± 2.0, Liver steatosis was scored as the percent-
age of hepatocytes containing macrovesicular fat droplets, it
ranged from 20% to 55% with mean of 41%. Grade1 steatosis
was present in 12 (15.8%), grade 2 and 3 in 64 (84.2%). Liver
ﬁbrosis ranged from 1 to 3. Grades 1 and 2 ﬁbrosis were pres-
ent in 22 (28.9%) patients, grade 3 in 54 (71.1%) patients.
Early virological response was achieved among 37 patients
(48.7%).
We investigated the difference between patients with
IR > 2 and patients with IR 6 2: We found no signiﬁcant dif-
ference in EVR, the difference was in the mean age and waist
circumference. Percentage of liver steatosis that were higher in
patients with IR > 2.
But this difference did not reach the signiﬁcant value
(Table 2).
We investigated the correlation between IR and studied
parameters, and we found signiﬁcant positive correlation with
age, and degree of hepatic steatosis (Table 3).
We investigated the relation between necroinﬂammation
and hepatic steatosis and we found that the mean value of
percentages of liver steatosis were signiﬁcantly higher among
Table 4 Comparison between responders and non responders.
Non responders (N= 41) Responders (N= 35) t^/v2# p
Age, years, mean ± SD 52.4 ± 9.6 42.0 ± 11.9 4.235 <0.001*
Sex n (%)
Males (n= 51) 28 (68.3%) 23 (37.1%)
0.52 0.471
Females (n= 25) 13 (31.7%) 12 (62.9%)
BMI, kg/m2, mean ± SD 26.1 ± 1.4 25.2 ± 1. 3 3.020 0.003*
Waist cm, mean ± SD 84.4 ± 6.3 84.8 ± 6.5 0.280 0.780
ALT IU/dl, mean ± SD 57.1 ± 49.1 54.3 ± 49.2 0.251 0.802
Triglycerides, mg/dl, mean ± SD 205.9 ± 170.9 187.2 ± 40. 4 0.681 0.498
Cholesterol, mg/dl, mean ± SD 213.2 ± 17.8 214.5 ± 30.1 0.241 0.810
IR 1.8 ± 0.3 1.5 ± 0.4 0.463 0.643
Viral load
 Mild 17 (41.5%) 17 (48.5%)
1.524 0.467 Moderate 16 (39.0%) 9 (25.7%)
 Marked 8 (19.5%) 9 (25.7%)
Fibrosis, n (%)
 Grades 1–2 8 (19.5%) 14 (40%) 3.808 0.051*
 Grades 3–4 33 (80.5%) 21 (60%)
Grade of necroinﬂammation mean ± SD 11.1 ± 1.9 10.3 ± 2.1 1.666 0.100
Steatosis, %, mean ± SD 42.0 ± 8.1 40.1 ± 9.0 1.037 0.303
^ Independent t-test.
# Chi square test.
* p value is signiﬁcant.
72 W.M. Ezzat et al.patients with grade 3 and 4 ﬁbrosis (43.2 ± 7.8%) than
patients with Grades 1 and 2 ﬁbrosis (35.4 ± 8.1%) (p=
0.0001) and the score of necroinﬂammation Table 4 was di-
rectly correlated to liver steatosis (r= 0.684, p= 0.0001).
We studied the effects of the studied parameters on re-
sponse to treatment and it was found that lower ages; lower
BMI and lower grades of ﬁbrosis were the only predictors
for good EVR.
4. Discussion
In recent years, several studies reported association between
IR and chronic HCV infection especially with genotype 1and
4 [3,4]. Insulin resistance has impact on the natural history
of the disease and treatment outcomes, as it promotes hepatic
inﬂammation and ﬁbrosis and impairs rapid and sustained
virological response rates to combined pegylated interferon/
ribavirin therapy in chronic HCV [7,17–19]. The association
of IR and CHC ranged between 30% and 70%, the higher
association is with genotype 1 and 4 [20].
Given the association between IR and poor treatment re-
sponse in CHC, clinical trials of insulin-sensitizing drugs have
been proposed to improve treatment response [21]. So that,
our aim was to identify the role of insulin resistance as a dis-
ease modiﬁer affecting progression of liver ﬁbrosis and early
virological response in chronic HCV infection.
In the current study, IR was detected in 40.8% of our pa-
tients. Studying the impact of IR on EVR, we did not ﬁnd sig-
niﬁcant difference in the rate EVR between patients with
IR 6 2 and patients with IR > 2; this was in contradiction
with Eslam and his colleagues study who found that IR is a
major determinant of the early viral kinetic response to peg
interferon plus ribavirin, which has a great impact on subse-
quent rapid virological response and SVR in CHC patients.
This suggests that strategies to improve IR may have a positiveeffect on SVR and may be early monitored. This contradiction
may be referred to different ethnicity or genotyping of the
virus as they use larger numbers of Egyptians and Spanish pa-
tients [22]. In Ziada and colleagues’ study, a total of 140
chronic HCV Egyptian patients were divided into two groups
according to the homeostasis model assessment-IR (HOMA-
IR). Group 1 consisted of 48 chronic HCV patients with
HOMA-IRP2, and group 2 consisted of 92 chronic HVC pa-
tients without IR (HOMA IR< 2). All patients were treated
with combination therapy (pegylated interferon-alpha 2a plus
ribavirin) for 48 weeks and studied for viral kinetics through-
out the period of therapy [23]. They concluded that IR in
chronic HCV patients is associated with progressive ﬁbrosis
and slow viral kinetics, and could be a predictor for lack of ra-
pid and sustained virological response. Therefore, HOMA-IR
levels should be measured and improved before starting antivi-
ral treatment. The contradiction between the current study and
Ziada and colleagues’ study was due to larger number of the
studied patients and in Ziada and colleagues’ study they use
SVR instead of EVR.
Camma´ and colleagues [24] reported that moderate/severe
steatosis and not IR are associated with low likelihood of
SVR in G1 HCV patients. Also in a study conducted on 155
HCV/HIV co infected patients at high prevalence of IR, IR
was not predictor of SVR to pegylated interferon plus ribavirin
This study identiﬁes HCV genotype, viral load and baseline
LDL cholesterol levels as independent predictors of SVR but
the impact of steatosis was not evaluated [9].
On the other hand several other studies reported associa-
tion between IR and virological response. Romero-Gomez
and colleagues [7] demonstrated lower rate of SVR among
genotype1 CHC patients with IR compared to those without
IR (32.8% vs. 60.5%). Also Conjeevaram and colleagues [8]
conﬁrmed the independent association between IR and SVR
rate in G1 African-American and White-American infected
Insulin resistance and early virological response in chronic HCV infection 73patients with a mean HOMA value ranging from 3.5 to 6.8.
Also in Asiatic patients with G1 CHC, IR, but not steatosis,
was an independent predictor of poor response to antiviral
treatment [25].
A similar result was reported in obese HCV patient with
genotypes 2 and 3 [19] and a recent study on genotype 4 re-
ported signiﬁcant association between IR and SVR, RVR [18].
The contradictory results may be related to the difference in
the baseline characteristics of patients such as ethnicity, BMI,
levels of serum cholesterol and triglycerides, degree of steatosis
and viral factors such as viral genotype and baseline viral load.
In the present study, we did not ﬁnd direct association
between IR and hepatic ﬁbrosis nor necroinﬂammation. This
is similar to the result obtained by Yoneda and colleagues
[26]. On the other hand other studies showed a link between
hepatic ﬁbrosis from CHC infection and IR, particularly for
obese patients and those with severe ﬁbrosis (stages 3–4)
[27,28].
There was a direct correlation between IR and liver steato-
sis. Consequently, there was a signiﬁcant correlation between
liver steatosis, and score of liver inﬂammation and grades of
liver ﬁbrosis. So, we may deduce that IR has an indirect effect
on liver inﬂammation and liver ﬁbrosis.
This lack of direct association may be due to the fact that
the global level of insulin resistance is likely to depend on
the contribution from the adipose tissue and the muscle, two
extra hepatic compartments that are not infected by HCV.
This result may suggest that the IR in HCV-infected patients
may be independent of hepatic inﬂammation or ﬁbrosis.
In the current study IR was not associated with viral load
which is contradictory to previous studies that showed associ-
ation of IR with HCV RNA level [4,25,29,30].
The relation between HCV and IR is a complex one it is not
evident whether IR stimulates viral replication or HCV in-
creases IR. Hepatitis C core protein promotes degradation of
insulin receptor substrate-1(IRS1) and induces insulin resis-
tance. The up regulation of IL6 and TNFa in CHC cause
reduction of hepatic insulin receptor autophosphorylation
and phosphorylation of IRS1 and 2 in cell culture and mice
and interfere with the insulin signaling cascade [5,31,32]. On
the other hand, IR promotes hepatic inﬂammation and ﬁbrosis
by inducing steatosis [33].
5. Conclusion
Insulin resistance is a common ﬁnding in CHC, it is associated
with increase liver steatosis. However it has no impact on EVR
to combined interferon ribavirin therapy, viral load or
necroinﬂammation.
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